| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — | — |
| Current Ratio | 1.16 | 2.55 | 0.06 | 1.12 | 16.05 | 0.53 | — |
| Quick Ratio | 1.16 | 2.55 | 0.06 | 1.12 | 16.05 | 0.53 | — |
| Debt / Equity | 0.90 | 0.33 | — | 0.13 | 0.04 | 0.86 | 2.78 |
| ROE | -894.81% | -208.51% | 342.60% | -455.34% | -99.36% | -555.82% | — |
| ROA | -148.94% | -104.58% | -674.08% | -154.99% | -90.49% | -124.12% | — |
| Asset Turnover | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
| Book Value / Share | 0.50 | 4.89 | -7.59 | 6.44 | 2.81 | 27.43 | — |
Cingulate Inc. is a clinical-stage biopharmaceutical company that develops pharmaceutical products using a proprietary precision timed-release drug delivery platform. The company concentrates on treatments for attention deficit/hyperactivity disorder and anxiety, aiming to provide medications that deliver more consistent therapeutic coverage over the day while reducing the need for multiple daily doses. Its lead product candidate, CTx-1301 (dexmethylphenidate), is being developed for ADHD, and additional candidates such as CTx-2103 (buspirone) target anxiety and broader mental health conditions. By focusing on frequently diagnosed conditions that often have burdensome dosing regimens and variable outcomes, Cingulate seeks to address unmet needs in neuropsychiatric care. The company operates in the healthcare sector within the biotechnology industry and is headquartered in Kansas City, Kansas, in the United States.